Gene Literature Dashboard

Viewing October 1979 — 2 paper(s) from the local store. (Local view only — run without --view to fetch new papers.)
← September 1979 November 1979 →
Also flagged:Delayed-type hypersensitivityantigensmajor histocompatibility complexcell-surface
Journal Article 1979-10-01 No Snippets Smith FI, Miller JF.
Show Full Abstract

DTH could be induced to cell-surface antigens coded by either H-2 or non-H-2 genes. Sensitivity was more readily induced across I region than across K- or D-region differences. The presence of an I-region difference during sensitization did not significantly increase the DTH response to K- or D-region-coded antigens. Macrophage processing appeared to be the major route of sensitization to background antigens. Thus, high levels of sensitivity were achieved equally well using viable or disrupted cells, the response was independent of the H-2 haplotype of the allogeneic cells, and transfer was restricted to the K end of the host H-2 complex. Although sensitization to H-2 antigens was obtained with disrupted cells, transfer of sensitivity against viable cells was unrestricted. This suggests a minor role for macrophage processing in sensitization to H-2 antigens.

Also flagged:cytosine arabinosidemonophosphateovalbuminantibodyuracil arabinosidenucleosides
Journal Article 1979-10-01 No Snippets Piall EM, Aherne GW, Marks VM.
Show Full Abstract

A radioimmunoassay (RIA) for cytosine arabinoside (AraC) has been developed using antiserum raised in a sheep to an AraC monophosphate-ovalbumin conjugate. The antibody shows only 0.008% cross-reactivity with uracil arabinoside (AraU) and low (0.023%) cross-reactivity with other commonly co-administered drugs such as cytotoxic and antibacterial agents, and also a number of naturally occurring nucleosides and nucleotides. It does however cross-react by 125% with AraC monophosphate and by 109% with AraC triphosphate. As little as 1 ng/ml of AraC can be detected in plasma, serum, urine and cerebrospinal fluid (CSF) with no need for prior extraction. This RIA has been used to follow the disappearance of AraC from the plasma of patients receiving the drug.